Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening

Gastroenterology

Volumn 141, Issue 5, 2011, Pages 1648-1655.e1

  Wilschut, Janneke A ^a   Hol, Lieke ^a   Dekker, Evelien ^b   Jansen, Jan B ^c   Van Leerdam, Monique E ^a   Lansdorp Vogelaar, Iris ^a   Kuipers, Ernst J ^a   Habbema, J Dik F ^a   Van Ballegooijen, Marjolein ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ELKERLIEK HOSPITAL   (Netherlands)

Author keywords

Colon Cancer; Colorectal Neoplasia; Cost Analysis; Decision Support Analysis

Indexed keywords

HEMOGLOBIN;

ARTICLE; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; FECAL IMMUNOCHEMICAL TESTING; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOCHEMISTRY; MODEL; PATIENT REFERRAL; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 80054857420     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.07.020     Document Type: Article

References (35)

1. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-1477. (Pubitemid 26400242)
2. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-1471. (Pubitemid 26400241)
3. Mandel JS, Church TR, Ederer F, et al. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999;91:434-437. (Pubitemid 29128279)
4. Benson VS, Patnick J, Davies AK, et al. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer 2008;122:1357-1367. (Pubitemid 351287237)
5. Pignone M, Saha S, Hoerger T, et al. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:96-104. (Pubitemid 34779153)
6. Hol L, Wilschut JA, van Ballegooijen M, et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009;100:1103-1110.
7. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135:82-90. (Pubitemid 351899018)
8. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010;59:62-68.
9. van Roon AH, Wilschut JA, Van Leerdam ME, et al. Costs of guaiac versus immunochemical fecal occult blood testing within a randomized population-based colorectal cancer screening trial. Gastroenterology 2010;138:S189-S190.
10. Loeve F, Boer R, van Ballegooijen M, et al. Final report MISCANCOLON microsimulation model for colorectal cancer: report to the National Cancer Institute Project No. NO1-CN55186: Department of Public Health, Erasmus University, 1998.
11. Loeve F, Boer R, van Oortmarssen GJ, et al. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res 1999;32:13-33. (Pubitemid 29102594)
12. Vogelaar I, van Ballegooijen M, Zauber AG, et al. Model Profiler of the MISCAN-Colon microsimulation model for colorectal cancer. Department of Public Health, Erasmus MC, 2004.
13. Lemmens V, van Steenbergen L, Janssen-Heijnen M, et al. Trends in colorectal cancer in the south of the Netherlands 1975-2007: rectal cancer survival levels with colon cancer survival. Acta Oncol 2010;49:784-796.
14. Lansdorp-Vogelaar I, van Ballegooijen M, Boer R, et al. A novel hypothesis on the sensitivity of the fecal occult blood test: results of a joint analysis of 3 randomized controlled trials. Cancer 2009; 115:2410-2419.
15. Loeve F, Boer R, Zauber AG, et al. National Polyp Study data: evidence for regression of adenomas. Int J Cancer 2004;111: 633-639. (Pubitemid 39045333)
16. Vogelaar I, van Ballegooijen M, Schrag D, et al. How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment. Cancer 2006;107:1624-1633. (Pubitemid 44546924)
17. van Rossum LG, van Rijn AF, Laheij RJ, et al. Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br J Cancer 2009;101:1274-1281.
18. van Rijn JC, Reitsma JB, Stoker J, et al. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 2006;101:343-350. (Pubitemid 43381678)
19. Nagengast FM, Kaandorp CJ. [Revised CBO guideline 'Follow-up after polypectomy']. Ned Tijdschr Geneeskd 2001;145:2022-2025.
20. Colquhoun P, Chen HC, Kim JI, et al. High compliance rates observed for follow up colonoscopy post polypectomy are achievable outside of clinical trials: efficacy of polypectomy is not reduced by low compliance for follow up. Colorectal Dis 2004;6: 158-161. (Pubitemid 38660634)
21. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365-1371. (Pubitemid 23131388)
22. Weller D, Coleman D, Robertson R, et al. The UK colorectal cancer screening pilot: results of the second round of screening in England. Br J Cancer 2007;97:1601-1605. (Pubitemid 350249359)
23. de Kok IM, Polder JJ, Habbema JD, et al. The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening. Br J Cancer 2009;100: 1240-1244.
24. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, et al. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 2009;101:1412-1422.
25. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008; 100:630-641.
26. Siegel JE, Torrance GW, Russell LB, et al. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997;11:159-168. (Pubitemid 27086806)
27. Zorzi M, Barca A, Falcini F, et al. Screening for colorectal cancer in Italy: 2005 survey. Epidemiol Prev 2007;31:49-60.
28. Castiglione G, Grazzini G, Miccinesi G, et al. Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. J Med Screen 2002;9:99-103. (Pubitemid 35205230)
29. Chen LS, Liao CS, Chang SH, et al. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16). J Med Screen 2007;14:191-199.
30. Itoh M, Takahashi K, Nishida H, et al. Estimation of the optimal cut off point in a new immunological faecal occult blood test in a corporate colorectal cancer screening programme. J Med Screen 1996;3:66-71. (Pubitemid 126736078)
31. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134:1570-1595. (Pubitemid 351615355)
32. Allison JE, Tekawa IS, Ransom LJ, et al. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996;334:155-159. (Pubitemid 26017953)
33. Terhaar sive Droste JS, Craanen ME, Kolkman JJ, et al. Dutch endoscopic capacity in the era of colorectal cancer screening. Neth J Med 2006;64:371-373.
34. Ness RM, Holmes AM, Klein R, et al. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol 1999;94:1650-1657. (Pubitemid 29260460)
35. Ramsey SD, Andersen MR, Etzioni R, et al. Quality of life in survivors of colorectal carcinoma. Cancer 2000;88:1294-1303. (Pubitemid 30155164)